GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » E10

Amryt Pharma (Amryt Pharma) E10 : $-2.23 (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Amryt Pharma's adjusted earnings per share data for the fiscal year that ended in Dec. 2021 was $0.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2.23 for the trailing ten years ended in Dec. 2021.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-10), Amryt Pharma's current stock price is $ 14.70. Amryt Pharma's E10 for the fiscal year that ended in Dec. 2021 was $-2.23. Amryt Pharma's Shiller PE Ratio of today is .


Amryt Pharma E10 Historical Data

The historical data trend for Amryt Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma E10 Chart

Amryt Pharma Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -2.06 -2.20 -2.23

Amryt Pharma Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.23 - - -

Competitive Comparison of Amryt Pharma's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amryt Pharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's Shiller PE Ratio falls into.



Amryt Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amryt Pharma's adjusted earnings per share data for the fiscal year that ended in Dec. 2021 was:

Adj_EPS=Earnings per Share (Diluted) /CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=0.02/114.7000*114.7000
=0.020

Current CPI (Dec. 2021) = 114.7000.

Amryt Pharma Annual Data

per_share_eps CPI Adj_EPS
201203 -0.012 95.400 -0.014
201303 -0.327 97.800 -0.384
201403 -0.261 99.300 -0.301
201503 -3.383 99.600 -3.896
201612 -1.508 102.200 -1.692
201712 -4.218 105.000 -4.608
201812 -3.328 107.100 -3.564
201912 -4.150 108.500 -4.387
202012 -3.300 109.400 -3.460
202112 0.020 114.700 0.020

Add all the adjusted EPS together and divide 10 will get our e10.


Amryt Pharma  (NAS:AMYT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Amryt Pharma E10 Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Amryt Pharma (Amryt Pharma) Business Description

Traded in Other Exchanges
N/A
Address
196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Amryt Pharma (Amryt Pharma) Headlines